Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1987-3-26
pubmed:abstractText
When human platelets are incubated with 500 nM-PAF-acether (platelet-activating factor. 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) under equilibrium conditions (60 min, 22 degrees C, non-stirred suspensions), two classes of fibrinogen binding sites are exposed: one class with a high affinity [Kd (7.2 +/- 2.1) X 10(-8) M, 2367 +/- 485 sites/platelet, n = 9] and one class with a low affinity [Kd (5.9 +/- 2.4) X 10(-7) M, 26972 +/- 8267 sites/platelet]. Preincubation with inhibitors of cyclo-oxygenase (acetylsalicylic acid, indomethacin) or thromboxane synthetase (UK 38.485) completely abolishes high-affinity binding, leaving low-affinity binding unchanged. In contrast, ADP scavengers (phosphocreatine/creatine kinase or phosphoenol pyruvate/pyruvate kinase) completely prevent low-affinity binding, leaving high-affinity binding unaltered. Initial binding studies (2-10 min incubation) confirm these findings with a major part of the binding being sensitive to ADP scavengers, a minor part sensitive to indomethacin and complete blockade with both inhibitors. Increasing the temperature to 37 degrees C decreases the number of low affinity-binding sites 6-fold without changing high-affinity binding. Aggregation, measured as the rate of single platelet disappearance, then depends on high-affinity binding at 10 nM-fibrinogen or less, whereas at 100 nM-fibrinogen or more low-affinity binding becomes predominant. These findings point at considerable platelet activation during binding experiments. However, arachidonate metabolism [( 3H]arachidonate mobilization and thromboxane synthesis) and secretion [( 14C]serotonin and beta-thromboglobulin) are about 10% or less of the amounts found under optimal conditions (5 units of thrombin/ml 37 degrees C, stirring). We conclude that PAF-acether induces little platelet activation under binding conditions. The amounts of thromboxane A2 and secreted ADP, however, are sufficient for initiating high- and low-affinity fibrinogen binding via mutually independent mechanisms.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-1064044, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-13671378, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-14907713, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-3015954, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-5061935, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-5432063, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-567240, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-574143, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6150705, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6216929, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6222507, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6224787, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6263888, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6270196, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6280787, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6282365, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6286013, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6286773, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6293626, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6307106, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6326566, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6406629, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6482659, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6495262, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6587368, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6767512, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6795753, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6804126, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6870274, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-6882682, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-7006608, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-7023317, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-7037068, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-7240750, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-7350149, http://linkedlifedata.com/resource/pubmed/commentcorrection/3101672-7452084
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0264-6021
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
240
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
403-12
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
Platelet-activating factor (PAF-acether) induces high- and low-affinity binding of fibrinogen to human platelets via independent mechanisms.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't